PRINCETON, N.J. (AP) -- A key experimental liver cancer drug that Bristol-Myers Squibb Co. has been testing did not meet the main goal of a late-stage study.
However, the company says three other late-stage studies of brivanib (BRIH'veh-nib) are continuing as planned.
In the study just ended, brivanib was being tested against placebo in liver cancer patients who had tried the cancer drug sorafenib (sor-EH'fehn-ib) and either couldn't tolerate it or had their cancer worsen.
The study was meant to show whether giving brivanib after patients failed on that drug would increase overall survival. It did not. There are few options for liver cancer patients if sorafenib doesn't work.
Bristol-Myers has said it planned next year to seek U.S. and European Union approval of brivanib.
(Copyright 2011 by The Associated Press. All Rights Reserved.)